Savara Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 59

Employees

  • Stock Symbol
  • SVRA

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $3.26
  • (As of Tuesday Closing)

Savara General Information

Description

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Contact Information

Website
www.savarapharma.com
Formerly Known As
Savara Pharmaceuticals, Adventrx Pharmaceuticals Inc, Biokeys Pharmaceuticals Inc
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • One Summit Square, 1717 Langhorne Newtown Road
  • Suite 300
  • Langhorne, PA 19047
  • United States
+1 (512)
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Life Sciences
Corporate Office
  • One Summit Square, 1717 Langhorne Newtown Road
  • Suite 300
  • Langhorne, PA 19047
  • United States
+1 (512)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Savara Stock Performance

As of 29-Apr-2025, Savara’s stock price is $3.26. Its current market cap is $563M with 173M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.26 $3.19 $2.25 - $5.31 $563M 173M 940K -$0.48

Savara Financials Summary

As of 31-Dec-2024, Savara has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 334,138 334,138 494,272 68,783
Revenue 0 0 0 0
EBITDA (102,218) (102,218) (59,057) (37,895)
Net Income (95,881) (95,881) (54,698) (38,150)
Total Assets 212,879 212,879 177,564 139,777
Total Debt 26,735 26,735 26,491 26,142
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Savara Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Savara‘s full profile, request access.

Request a free trial

Savara Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Savara‘s full profile, request access.

Request a free trial

Savara Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramost
Biotechnology
Langhorne, PA
59 As of 2024

Chicago, IL
 

Westlake Village, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Savara Competitors (23)

One of Savara’s 23 competitors is Xeris Biopharma Holdings, a Formerly VC-backed company based in Chicago, IL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Xeris Biopharma Holdings Formerly VC-backed Chicago, IL
MannKind Formerly VC-backed Westlake Village, CA
Windtree Therapeutics Corporate Backed or Acquired Warrington, PA
Nimbus Therapeutics Venture Capital-Backed Boston, MA
Zealand Pharma Formerly VC-backed Soborg, Denmark
You’re viewing 5 of 23 competitors. Get the full list »

Savara Patents

  • 114

    Total Documents Applications and Grants

  • Total Patents Families

  • 38

    Granted

  • 7

    Pending

  • Expiring in next 12 mo

Savara Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4249022-A1 Drug-device combination Inactive 21-Mar-2022
AU-2023240286-A1 Drug-device combination Pending 21-Mar-2022
EP-4496611-A1 Drug-device combination Pending 21-Mar-2022
JP-2025510120-A Drug-device combinations Pending 21-Mar-2022
US-20250064893-A1 Methods for the treatment of autoimmune pulmonary alveolar proteinosis Pending 02-Oct-2020 A61K38/193
To view Savara’s complete patent history, request access »

Savara Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Savara Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Savara‘s full profile, request access.

Request a free trial

Savara Investments & Acquisitions (3)

Savara’s most recent deal was a Corporate Asset Purchase with Cardeas Pharma (Inhaled Antibiotic Rights). The deal was made on 25-Jul-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cardeas Pharma (Inhaled Antibiotic Rights) 25-Jul-2018 Corporate Asset Purchase Buildings and Property
Mast Therapeutics 27-Apr-2017 Merger/Acquisition Pharmaceuticals
Serendex Pharmaceuticals 15-Jul-2016 Merger/Acquisition Buildings and Property
To view Savara’s complete investments and acquisitions history, request access »

Savara ESG

Risk Overview

Risk Rating

Updated February, 22, 2024

25.81 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Pharmaceuticals

Industry

of 861

Rank

Percentile

Biotechnology

Subindustry

of 371

Rank

Percentile

To view Savara’s complete esg history, request access »

Savara Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Aravas Austin, TX 2007

Savara FAQs

  • When was Savara founded?

    Savara was founded in 2007.

  • Where is Savara headquartered?

    Savara is headquartered in Langhorne, PA.

  • What is the size of Savara?

    Savara has 59 total employees.

  • What industry is Savara in?

    Savara’s primary industry is Biotechnology.

  • Is Savara a private or public company?

    Savara is a Public company.

  • What is Savara’s stock symbol?

    The ticker symbol for Savara is SVRA.

  • What is the current stock price of Savara?

    As of 29-Apr-2025 the stock price of Savara is $3.26.

  • What is the current market cap of Savara?

    The current market capitalization of Savara is $563M.

  • Who are Savara’s competitors?

    Xeris Biopharma Holdings, MannKind, Windtree Therapeutics, Nimbus Therapeutics, and Zealand Pharma are some of the 23 competitors of Savara.

  • What is Savara’s annual earnings per share (EPS)?

    Savara’s EPS for 12 months was -$0.48.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »